# Safety and Immune Response to Preventive HIV Immunization With Adenovirus Serotype 5 or 35 Vector

> **NCT00801697** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 192 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** DNA Vaccine
- **BIOLOGICAL:** DNA Vaccine placebo
- **BIOLOGICAL:** rAd35
- **BIOLOGICAL:** rAd35 placebo
- **BIOLOGICAL:** rAd5
- **BIOLOGICAL:** rAd5 placebo

## Key facts

- **NCT ID:** NCT00801697
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2011-02
- **Final completion:** 2015-04
- **Target enrollment:** 192 (ACTUAL)
- **Last updated:** 2021-10-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00801697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00801697, "Safety and Immune Response to Preventive HIV Immunization With Adenovirus Serotype 5 or 35 Vector". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00801697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*